Yüklüyor......
Early experience of seven hepatocellular carcinoma cases treated with regorafenib
Regorafenib became second‐line treatment for the patients with sorafenib refractory. In our study, two patients could not continue regorafenib for its adverse effects. It was suggested that appropriate use criteria of regorafenib should be observed and manage adverse effects earlier.
Kaydedildi:
| Yayımlandı: | Clin Case Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6230610/ https://ncbi.nlm.nih.gov/pubmed/30455925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1791 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|